Jamp-Hydralazine tablet: Affected lot may contain Jamp-Hydralazine 10 mg tablets
Brand(s)
Last updated
Summary
Product
Jamp-Hydralazine tablet
Issue
Health products - Product safety
What to do
Consult your health care professional if you have any health concerns.
Affected products
| Brand | Product Name | Market Authorization | Dosage Form | Strength | Lot number |
|---|---|---|---|---|---|
| Jamp Pharma | Jamp-Hydralazine tablet | DIN 02457873 | Tablet | Hydralazine hydrochloride 25 mg | H0224009F |
Issue
The affected lot (Jamp-Hydralazine 25 mg) may contain Jamp-Hydralazine 10 mg tablets.
What you should do
- Verify if your product is affected.
- Consult your healthcare provider prior to discontinuing use of the affected product(s), or for any health concerns.
- Contact the recalling firm if you have any questions about the recall.
- Report any health product related side effects to Health Canada.
- Report any other health product safety complaints to Health Canada.
Additional information
Background
Depth of recall: Retailers
Details
Original published date:
Alert / recall type
Health product recall
Category
Health products - Drugs
Companies
JAMP PHARMA CORPORATION
1310 rue Nobel,
Boucherville QC J4B 5H3 Canada
Published by
Health Canada
Audience
General public
Healthcare
Industry
Recall class
Type II
Identification number
RA-77577
Get notified
Receive notifications for new and updated recalls and alerts by category.